2013年国际抗癫痫联合会抗癫痫解毒使用指南
2022-04-25 01:58:04 来源: 湛江 咨询医生
he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信道地址
- 2022-04-252013年国际抗癫痫联合会抗癫痫解毒使用指南
- 2022-02-28癫痫病诊断的依据是什么
- 2019-04-16癫痫初期有哪些发病的症状
- 抗癫痫药物预防新发癫痫:任重而道远
- AP&T:女性炎性肠病患者早期停用TNF-α抑制剂与更大的副作用风险有关
- FDA批准塞尔基因Otezla治疗银屑病性关节炎
- 中华医学会系列精选指南|急性腹痛、淋巴瘤、银屑病的诊断和治疗
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- FDA 批准银屑病新药 ixekizumab
- 癫痫猝死:凶手是谁?
- 箕星宣布aficamten在中国获得突破性治疗药物认定
- 疾病新知:毛囊性白癜风
- 心房颤动和扑动心电图诊断要点
- 如何预防遗传?
- 试验性依那西普生物类似物 CHS-0214 3 期研究的主要终点
- 黑头怎么去?
- 癫痫治疗障碍仍难以克服
- 如何最有效地去除黑头?
- 冬病夏治银屑病优势
- 月经性癫痫患者妊娠期癫痫控制更好
- 生发偏方 4种生发偏方使头发更浓密
- 羊角风有什么症状?
- 不简单 找出病因更好解决
- 夏季生活常识 酷夏保健秘籍你知道多少(2)
- 临床试验显示XenoPort 银屑病药物胃肠道副作用较严重
- 最新!最近,创新药获得了世界上第一批!
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 注射激素会导致外周色素减少和萎缩
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 为什么女性癫痫病很难治愈
- 20130301山东卫视明目节目:安晓光谈癫痫病病因
- 癫痫病小猝死症状 这些症状就是癫痫小猝死
- 癫痫病诊断的依据是什么
- 造成患者癫痫反复发烧的原因到底是什么?
- 治癫痫病哪里好特性好吗
- 心理维基:解读“幼稚病”
- 癫痫病症状 怎样保健癫痫病人
- 临床如何诊断是否抑郁症轻度癫痫
- 恶性胶质瘤国际新疗法——详解雷射间质热疗(LITT)
- 原发癫痫病能治疗者吗
- Circ Ep:腺苷试验可判别复发AF消融术时的隐匿传导静脉
- 国医养生堂:徐全兴讲如何预防儿童癫痫